Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
33 Analysts have issued a AstraZeneca forecast:
33 Analysts have issued a AstraZeneca forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 43,894 43,894 |
14%
14%
|
|
| Gross Profit | 35,948 35,948 |
13%
13%
|
|
| EBITDA | 13,754 13,754 |
21%
21%
|
|
| EBIT (Operating Income) EBIT | 10,685 10,685 |
26%
26%
|
|
| Net Profit | 7,098 7,098 |
45%
45%
|
|
In millions GBP.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
| Head office | United Kingdom |
| CEO | Pascal Soriot |
| Employees | 94,300 |
| Founded | 1992 |
| Website | www.astrazeneca.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


